Last reviewed · How we verify
CD19-BCMA CAR-T cells infusion
At a glance
| Generic name | CD19-BCMA CAR-T cells infusion |
|---|---|
| Sponsor | Beijing GoBroad Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases (NA)
- A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. (PHASE1, PHASE2)
- A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) (PHASE1)
- A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (PHASE1, PHASE2)
- Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. (PHASE1, PHASE2)
- CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH (PHASE1, PHASE2)
- UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases (EARLY_PHASE1)
- A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD19-BCMA CAR-T cells infusion CI brief — competitive landscape report
- CD19-BCMA CAR-T cells infusion updates RSS · CI watch RSS
- Beijing GoBroad Hospital portfolio CI